Smarter cancer care

Exact Sciences delivers the promise and value of precision medicine with the Oncotype DX^® test.

NEWS

ASCO Guidelines 2022

Updated ASCO Guidelines strongly recommend use of the Oncotype DX Breast Recurrence Score^® Test in node-negative and the majority of node-positive early-stage breast cancer patients.

ASCO is a trademark of the American Society of Clinical Oncology.
ASCO does not endorse any product or therapy.

LEARN MORE

GUIDELINES

NCCN Breast Cancer Guidelines

New NCCN Breast Cancer Guidelines recognize Oncotype DX Breast Recurrence Score^® as the “preferred” and only multigene test to predict chemotherapy benefit in node-positive early-stage breast cancer

View Details

Deborah, an Oncotype DX patient

How Oncotype DX works and how it can help guide a tailored chemotherapy treatment decision for all your HR+, HER2-, early-stage breast cancer patients:

Oncotype DX® tests

Breast Cancer

New Data

The only multigene expression genomic test commercially available proven to predict a patient’s individual benefit from chemotherapy.

Learn More

Breast Cancer

Improving Patient Outcomes

What Is the Test

The Oncotype DX test reveals the underlying tumour biology to help guide treatment decisions.

Learn More

Getting Tested

The Oncotype DX^® test should be used when the benefit of chemotherapy for a patient is uncertain.

LEARN MORE

Latest TAILORx Data

The landmark TAILORx results provide definitive answers on which early stage ER+, HER2-, N0 breast cancer patients can benefit from chemotherapy.

Latest TAILORx Data

The landmark TAILORx results provide definitive answers on which early stage ER+, HER2-, N0 breast cancer patients can benefit from chemotherapy.

Learn More

Contact Us

GET IN TOUCH

You are now leaving this site. Any third party link you select from this site may take you to an Exact Sciences website intended for US audiences or a website that is not affiliated with Exact Sciences.

I Agree